We are transforming the process of antibody discovery to enable targeting protein receptors such as GPCRs. These receptors are embedded in cell membranes and very challenging to work with in the lab. By moving discovery from the bench to the digital world, we are set free from limitations of lab-intensive assays. We can identify promising new antibody candidates significantly faster, with higher hit rates, reduced risks associated with lab-based drug development.